Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro by Nguyen, Jack T. et al.
Triple Combination of Amantadine, Ribavirin, and
Oseltamivir Is Highly Active and Synergistic against Drug
Resistant Influenza Virus Strains In Vitro
Jack T. Nguyen
1*, Justin D. Hoopes
2, Minh H. Le
1, Donald F. Smee
2, Amy K. Patick
1, Dennis J. Faix
3,
Patrick J. Blair
3, Menno D. de Jong
4, Mark N. Prichard
5, Gregory T. Went
1*
1Adamas Pharmaceuticals, Inc., Emeryville, California, United States of America, 2Utah State University, Logan, Utah, United States of America, 3Naval Health Research
Center, San Diego, California, United States of America, 4Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 5University of Alabama,
Birmingham, Alabama, United States of America
Abstract
The rapid emergence and subsequent spread of the novel 2009 Influenza A/H1N1 virus (2009 H1N1) has prompted the
World Health Organization to declare the first pandemic of the 21
st century, highlighting the threat of influenza to public
health and healthcare systems. Widespread resistance to both classes of influenza antivirals (adamantanes and
neuraminidase inhibitors) occurs in both pandemic and seasonal viruses, rendering these drugs to be of marginal utility
in the treatment modality. Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes
(rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely
prescribed neuraminidase inhibitor (NAI). To address the need for more effective therapy, we evaluated the in vitro activity
of a triple combination antiviral drug (TCAD) regimen composed of drugs with different mechanisms of action against drug-
resistant seasonal and 2009 H1N1 influenza viruses. Amantadine, ribavirin, and oseltamivir, alone and in combination, were
tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells. Our
data show that the triple combination was highly synergistic against drug-resistant viruses, and the synergy of the triple
combination was significantly greater than the synergy of any double combination tested (P,0.05), including the
combination of two NAIs. Surprisingly, amantadine and oseltamivir contributed to the antiviral activity of the TCAD regimen
against amantadine- and oseltamivir-resistant viruses, respectively, at concentrations where they had no activity as single
agents, and at concentrations that were clinically achievable. Our data demonstrate that the TCAD regimen composed of
amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1. The TCAD regimen
overcomes baseline drug resistance to both classes of approved influenza antivirals, and thus may represent a highly active
antiviral therapy for seasonal and pandemic influenza.
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Introduction
Globally, influenza viruses cause substantial morbidity and
mortality in humans and economic dislocation in afflicted nations.
Each year in the United States, seasonal influenza virus infection
result in an estimated 36,000 deaths and 200,000 hospitalizations
[1]. Antiviral drugs are an important means to mitigate the impact
of the yearly influenza epidemics and potential pandemics.
Currently, two classes of antiviral drugs have been approved for
the prevention and treatment of influenza infection – the M2
channel inhibitors (aminoadamantanes; amantadine and rimanta-
dine) and the neuraminidase inhibitors (NAIs; oseltamivir and
zanamivir). However, the prevalence of drug-resistant strains,
which has been reported for both classes of antiviral drugs for
seasonal influenza [2,3], could undermine their clinical benefit
when utilized as monotherapy. Indeed, in 2009, the Centers for
Disease Control and Prevention (CDC) reported that 100% of the
seasonal H3N2 virus isolate tested were resistant to the
adamantanes, and 99.6% of the seasonal H1N1 viruses tested
were resistant to oseltamivir [4].
In April, 2009, a novel H1N1 virus of swine-origin capable of
human-to-human transmission likely emerged in Mexico and was
first isolated from patients enrolled in two separate surveillance
activities in Southern California [5]. The emergence and spread of
2009 H1N1 to over 168 countries has led U.S. officials [6] and the
World Health Organization (WHO) [7] to declare a public health
emergency; on June 11, 2009 the WHO raised the influenza
pandemic alert from phase 5 to phase 6, the official declaration of
a pandemic [8]. Early published results from the CDC showed
that 2009 H1N1 bears the amantadine-resistance associated S31N
mutation in the M2 ion channel, but remains susceptible to
oseltamivir and zanamivir [9]. More recently, however, the CDC
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States have been found to be resistant to oseltamivir, raising the
concern that dually resistant viruses may become prevalent [4].
In an earlier study, we explored the in vitro antiviral activity and
synergy of single, double, and triple combinations of amantadine,
ribavirin and oseltamivir against a panel of influenza A viruses that
were susceptible to these drugs [10]. Our hypothesis was that a
triple combination antiviral drug (TCAD) regimen composed of
drugs with different mechanisms of action, and which act at
different stages in the viral life cycle, could result in synergistic
antiviral activity. Our results showed that these drugs did indeed
act synergistically, with the triple combination showing signifi-
cantly greater synergy than any of the double combinations
evaluated. Furthermore, we found that the synergy of the TCAD
regimen was maintained across multiple seasonal and avian
influenza A strains, including the three major subtypes – A/H1N1,
A/H3N2, and the avian A/H5N1 – that currently cause
significant morbidity and mortality in humans.
In this study, we sought to evaluate the activity and synergy of
the TCAD regimen against influenza viruses which were resistant
to amantadine or oseltamivir. Our data showed that against
amantadine-resistant viruses – both seasonal and 2009 H1N1 –
and oseltamivir-resistant seasonal viruses, the TCAD regimen was
strongly synergistic, and the synergy of the TCAD regimen was
greater than the synergy of any double combination. Surprisingly,
we found that amantadine and oseltamivir contributed to the
synergy of the TCAD regimen at concentrations where they had
no activity as single agents, and at concentrations that were
clinically achievable. Our findings highlight the utility of the
TCAD regimen as a potential approach to address the current
limitations of antiviral potency and drug resistance, and as a viable
broad-spectrum therapeutic option for serious influenza virus
infection.
Materials and Methods
Antiviral Compounds
Oseltamivir carboxylate, the active metabolite of oseltamivir,
was obtained from Charnwood Molecular (Loughborough, U.K.)
through synthesis via the NBoc-protected acid from oseltamivir
phosphate. Amantadine was obtained from Moehs Catalana
(Barcelona, Spain). Ribavirin and rimantadine were purchased
from Sigma-Aldrich (St. Louis, MO). Peramivir was obtained from
Jubilant Chemsys LTD (Uttar Pradesh, India) as free base through
NBoc synthesis, and purity was confirmed using NMR and chiral
HPLC. Zanamivir was obtained from Haorui Pharma-Chem, Inc.
(Edison, NJ).
Influenza Viruses
Two 2009 H1N1 strains – influenza A/California/05/09
(H1N1) and influenza A/California/10/09 (H1N1) – were
obtained from the Naval Health Research Center as the result
of ongoing influenza surveillance studies. A third 2009 H1N1
strain, A/California/04/10 (H1N1) was received from the Centers
for Disease Control and Prevention (CDC, Atlanta, GA).
Influenza A/New Caledonia/20/99 (H1N1) was provided by
the CDC, and the amantadine-resistant V27A mutant was
generated by passaging in Madin-Darby canine kidney (MDCK)
cells in the presence of amantadine. Influenza A/Duck/1525/81
(H5N1) was provided by Dr. Robert Webster (St. Jude Children
Research Hospital, Memphis, TN), and the A30T amantadine-
resistant mutant was generated by passaging in MDCK cells in the
presence of amantadine. The oseltamivir-resistant influenza A/
Mississippi/3/01 (H1N1) [H274Y] was provided by the Neur-
aminidase Inhibitor Surveillance Network (Melbourne, Australia),
and the oseltamivir-resistant A/Hawaii/21/07 (H1N1) was kindly
provided by Dr. Larisa Gubareva (CDC, Atlanta, GA). The
viruses were passaged in MDCK cells (American Type Culture
Collection, Manassas, VA) to create working stocks, which were
used for the antiviral assays. Additionally, the genotype of the
matrix protein 2 (M2), hemagglutinin (HA), and neuraminidase
(NA) for each virus were confirmed by Sanger sequencing.
Cells and Growth Medium
Cells were passaged in minimal essential medium containing
5% fetal bovine serum (Hyclone Laboratories, Logan, UT).
During antiviral evaluations, the serum was removed and the
medium was supplemented with gentamicin (50 mg/mL), porcine
trypsin (10 units/mL) and EDTA (1 mg/mL).
Cell-Based Assays
To obtain single agent concentration-response curves, individ-
ual drugs were added to MDCK cells in 96-well microplates
(8610
4 cells/well) using three wells for each concentration used.
The compounds were added at the following concentrations:
oseltamivir carboxylate, zanamivir, and peramivir at 0, 0.000032,
0.0001, 0.00032, 0.001, 0.0032, 0.01, 0.032, 0.1, 1.0, 10.0 and
100 mg/mL; amantadine, rimantadine, and ribavirin at 0, 0.001,
0.0032, 0.01, 0.032, 0.1, 0.32, 1, 3.2, 10, 32 and 100 mg/mL.
Untreated wells of infected cells (virus controls), uninfected cells
(cell controls), and drug cytotoxicity controls (cells and drugs only,
using the same dilution range for each drug as the test wells) were
included on each test plate. At three days after infection, the virus
control wells exhibited 100% cytopathology. The 50% effective
concentration (EC50) and 50% cytotoxic concentration (TC50) was
determined for each drug as outlined below.
For double and triple combination studies, each drug was tested
in triplicate at five or six concentrations (including no drug), in
which the high concentration for each drug was set to approximate
the EC50 of the drug as a single agent. The concentrations of each
drug used in double and triple combinations against each virus are
provided in Table S1. The cytotoxicity of the double and triple
drug combinations were determined using the same experimental
format in three separate experiments, and using the same
concentration ranges as outlined in Table S1.
The extent of viral cytopathology in each well was determined
by staining with Neutral Red (NR) as detailed elsewhere [11].
Briefly, the cells were stained with 0.011% NR diluted in MEM to
determine cell viability. Two hours later the plates were processed
for quantification of NR uptake into viable cells. The amount of
NR taken up by cells was determined spectrophotometrically.
EC50,T C 50, and Synergy Calculations
EC50,T C 50, and synergy calculations were done as described
previously [10]. Briefly, EC50 and TC50 calculations for single
agents were made by normalizing the NR data for each well
against the cell and virus controls, which was assumed to represent
100% cell viability and 0% cell viability, respectively. Normalized
data were plotted as percent cell viability versus compound
concentration. The data points were then fitted using four-
parameter curve fitting in Graphpad Prism (Graphpad Software,
La Jolla, CA) to derive the EC50 and TC50. Statistical comparisons
between best-fit EC50 values for any two curves were performed in
Prism using the extra sum-of-squares F test; differences in EC50
values between two curves with a P-value of ,0.05 were
considered significant.
Synergy was calculated using the MacSynergy II software
developed by Prichard and Shipman, which was modified to
Combination Drug for Influenza
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9332accommodate a three-drug combination [12] and is similar to that
reported previously describing this approach [13]. The theoretical
additive interactions were calculated from the concentration-
response curves of each drug as a single agent. This calculated
additive surface was then subtracted from the observed, experi-
mental surface to reveal regions that deviate from the calculated
additive effects. Purely additive interactions are represented
graphically as areas in grey, indicating that they do not differ
from the calculated additive effects. Synergistic interactions result
in greater inhibition than the calculated inhibition, and are
represented as areas in blue. Conversely, antagonism is represent-
ed as areas in red. Synergy plots are shown as the percent
inhibition above or below expected (calculated additive inhibition),
and are presented as the mean of three replicates at a level of 95%
confidence, which eliminates insignificant deviations from the
additive surface.
Synergy volume for each double and triple combination was
also calculated, which represents the sum of the synergy or
antagonism across all concentrations of a combination. Synergy
volumes are presented as a quantitative measure of the overall
interaction of the drugs within a combination. As determined by
cytopathic effect (Neutral Red assay), synergy volumes .100 mg/
mL
2% for double combinations or .100 mg/mL
3% for triple
combinations are considered to be strongly synergistic. Converse-
ly, combinations with synergy volumes ,2100 mg/mL
2%o rmg/
mL
3% are considered to be strongly antagonistic.
The synergy of the cytotoxic effects of double and triple drug
combinations were calculated in a similar manner.
Statistical Analysis of Synergy Volumes
Between three and nine independent experiments were
conducted using identical dosing ranges for amantadine, ribavirin,
and oseltamivir carboxylate against each virus. The experiments
used a 3-replicate plate format, for a total of 9 to 27 observations
for each condition. The data from the independent experiments
were merged and subjected to statistical analysis using the random
effects model. The raw data were imported into the program R
and were normalized to the virus and cell controls as described
above, and synergy (percent inhibition above calculated) is
calculated as above. For synergy volume estimates, random effects
models were applied to the data to account for variation between
replicate measures within experiments. Therefore, the models took
the form as given by:
Yij~b0zu0izeij
where Yij is the measure of the j
th replicate in experiment i; b0 is
the grand mean; u0i,N(0,t
2); and eij,N(0,s
2). As the observations
in the data are not independent, this model allowed for proper
estimation of standard errors. The standard errors were then used
to determine the statistical significance of synergy volume.
Determination of Inhibitory Quotient
The inhibitory quotient (IQ) is defined herein as the ratio of the
expected average total (free and protein-bound) plasma concen-
tration (Cave) of each drug at recommended dosage to the EC50
(Cave/EC50). Thus, an IQ of 1 or greater means that the
achievable total plasma concentration of the drug is equal to or
greater than the in vitro 50% effective concentration, and the
higher the IQ translates to a greater predicted efficacy. The Cave of
each drug was determined by pharmacokinetic modeling using a
non-compartmental model in the progam WinNonLin. The
recommended doses, along with the pharmacokinetic parameters,
used for modeling were obtained from the package inserts for
amantadine [14], oseltamivir [15], and ribavirin [16], and the
references therein. For ribavirin, since the plasma concentration
does not achieve steady-state until ,4 weeks after the start of
dosing, the Cave was determined for the first 10-day window.
Based on these parameters, the expected Cave for amantadine was
determined to be 0.43 mg/mL based on the recommended dosage
of 100 mg twice daily for the treatment of influenza infection; the
expected Cave for oseltamivir was determined to be 0.3 mg/mL
based on the recommended dosage of 75 mg twice daily for the
treatment of influenza infection; and the expected Cave of for
ribavirin was determined to be 1.3 mg/mL after 10 days of
treatment based on the recommended dosage of 600 mg twice
daily for the treatment of hepatitis C infection. To determine the
IQ of the triple combination, amantadine, ribavirin, and
oseltamivir carboxylate were tested as a fixed ratio combination,
wherein the ratio of the three drugs was kept constant even as the
total concentration of drugs varied. The ratio of drugs in the
TCAD regimen was based on the expected Cave of each drug. A
dilution curve of TCAD regimen was created by first preparing a
solution of all three drugs at 100-fold the Cave of each drug (43 mg/
mL amantadine, 30 mg/mL oseltamivir carboxylate, and 130 mg/
mL ribavirin), and then serially diluting this solution in 0.5-log10
increments. In this manner, the EC50 of TCAD regimen as a fixed
dose combination was determined as ratio of the Cave and
expressed in units of fold-Cave.
Results
Activity of Antiviral Drugs as Single Agents against 2009
H1N1
The susceptibility of three 2009 H1N1 influenza strains – A/
California/04/09 (CA04), A/California/05/09 (CA05) and A/
California/10/09 (CA10) – to each of six antiviral drugs
(amantadine, rimantadine, oseltamivir carboxylate, zanamivir,
peramivir, and ribavirin) as single agents was determined by
measuring the inhibition of virus-induced CPE in MDCK cells.
Against the three strains, oseltamivir carboxylate, zanamivir,
peramivir, and ribavirin produced concentration-dependent
inhibition of cytopathic effect (data not shown). Amantadine was
active only at higher concentrations (EC50 of 16–20 mg/mL; 85–
106 mM) (Table S2), which represents a .250-fold reduction in
susceptibility compared to the published values for a wild-type
virus[17]. Rimantadine did not produce inhibition up to the 50%
cytotoxic concentration (EC50.12 mg/mL; .55 mM). The EC50
values for the six drugs as single agents against all three strains are
summarized in Table S2, and confirm that the three virus strains
remain susceptible to oseltamivir carboxylate, zanamivir, perami-
vir, and ribavirin. These results are consistent with the results
previously published that demonstrated that 2009 H1N1 con-
tained a mutation (S31N) in the M2 channel that has been
associated with resistance to adamantanes, but remained suscep-
tible to NAIs [18].
Synergy of Double and Triple Combinations of
Amantadine, Ribavirin, and Oseltamivir Carboxylate
against 2009 H1N1
We next assessed the synergistic activity of double and triple
combinations of amantadine, ribavirin, and oseltamivir carboxyl-
ate over a range of concentrations of each drug against each 2009
H1N1 isolate. A quantitative measure of the total synergy (or
antagonism) of a drug combination can be expressed in terms of
synergy volumes, which represents the cumulative synergy and
antagonism across all concentrations for all the drugs in a
Combination Drug for Influenza
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synergy volume .100 mg/mL
2% using the lower confidence
interval, all three double combinations were additive against the
2009 H1N1viruses (Table 1). By contrast, the TCAD regimen was
synergistic against all three viruses over multiple concentrations of
all three drugs, with the synergy occurring at 0.1 mg/mL and
above for amantadine, 0.32 mg/mL and above for ribavirin, and
0.0032 mg/mL and above for oseltamivir carboxylate (Table 1).
These data show that the synergy of the TCAD regimen occurred
at clinically achievable concentrations for all three drugs, given
that the expected average plasma concentrations based on the
recommended doses are 0.43 mg/mL for amantadine, 1.3 mg/mL
for ribavirin, and 0.3 mg/mL for oseltamivir carboxylate. Fur-
thermore, the synergy of the TCAD regimen was greater than the
synergy of any double combination tested for all three 2009 H1N1
strains. Figure 1B–1D shows the synergy of the TCAD regiment as
a function of increasing concentrations of amantadine, ribavirin,
or oseltamivir carboxylate as the third drug, representing the
contribution of each drug to the synergy of the double
combination without the third drug. These data reveal that the
addition of each drug as the third drug to the double combinations
resulted in a concentration-dependent increase in synergy,
indicative that each drug contributed to the synergy of the TCAD
regimen.
Importantly, despite the fact that amantadine had no
significant antiviral activity as a single agent below 3.2 mg/mL
(data not shown), we find that the amantadine contributed to the
activity of the TCAD regimen at clinically achievable concen-
trations (0.43 mg/mL). Statistical analysis of the variability across
all replicates from the six experiments for each virus revealed that
amantadine made a significant contribution to the synergy of the
TCAD regimen at concentrations 0.1 mg/mL and 0.32 mg/mL
and above against CA05 and CA10, respectively, compared to
the double combination of ribavirin/oseltamivir carboxylate
without amantadine (Figure 1B). For CA04, while only the
3.2 mg/mL amantadine concentration had statistically significant
greater synergy volume than the double combination without
amantadine, there was a trend toward increasing synergy volume
starting at 0.32 mg/mL. Thus, amantadine contributed to the
activity of the TCAD regimen at concentrations where it was
inactive as a single agent, and at concentrations that were
clinically achievable.
Synergy plots, which reveal the extent of synergy at each
concentration of each drug in the combinations, are shown in
Figures S1 for CA05. The data are presented as contour plots, in
which regions where inhibition is greater (synergy) or less
(antagonism) than expected are identified by subtracting the
theoretical additive inhibition from the observed inhibition.
Synergy plots for TCAD regimen showed a concentration-
dependent increase in synergy with respect to amantadine
(Figure S1B, top plane). At the highest concentration tested
(3.2 mg/mL), synergy was observed over a wide range of
concentrations of ribavirin and oseltamivir carboxylate tested.
At lower concentrations of amantadine, synergy occurred at
1 mg/mL ribavirin and higher, and at 0.0032 mg/mL oseltamivir
carboxylate and higher. No significant antagonism was observed
at any dose of any drug in the double combinations or the TCAD
regimen. Similar patterns of synergy were observed with double
and triple combinations of these antiviral drugs against CA04
and CA10 (data not shown).
Enhancement of Antiviral Drug Activity in Triple
Combination against 2009 H1N1
One notable consequence of synergy is that the antiviral
activities of each drug in the combination is enhanced compared
to the activities of the drugs as single agents. To demonstrate this,
we compared the antiviral activity of each of the three drugs –
amantadine, ribavirin, and oseltamivir carboxylate – as single
agents and in the presence of fixed concentrations of the second
and third drugs against CA10 replication. For each drug, the EC50
Table 1. Synergy volume of double and triple combinations
of antivirals against 2009 H1N1 viruses A/California/04/09
(CA04), A/California/05/09 (CA05), and A/California/10/09
(CA10) as determined by Neutral Red assay.
Regimen CA04 CA05 CA10
Double combinations
(mg/mL
2%)
Zanamivir/Oseltamivir
carboxylate
2246116 2155689 2197698
Zanamivir/Peramivir 2356112 21976108 2239693
Amantadine/Oseltamivir
carboxylate
1126154 133680 135667
Amantadine/Ribavirin 12682 22636 69659
Ribavirin/Oseltamivir
carboxylate
1786188 2226143 166673
TCAD at fixed
concentrations of
amantadine (mg/mL
3%)
0.1 mg/mL amantadine 1066208 3126195 226684
0.32 mg/mL amantadine 2926212 2936154 296682
1.0 mg/mL amantadine 3466212 3376196 3116139
3.2 mg/mL amantadine 4756221 485697 4136163
TCAD at fixed
concentrations of
ribavirin (mg/mL
3%)
0.1 mg/mL ribavirin 926119 146682 1716137
0.32 mg/mL ribavirin 1146250 135695 2716105
1.0 mg/mL ribavirin 1796292 4786138 3536108
3.2 mg/mL ribavirin 6916144 7636256 6326216
TCAD at fixed
concentrations of
oseltamivir carboxylate
(mg/mL
3%)
0.001 mg/mL oseltamivir
carboxylate
66692 104653 153684
0.0032 mg/mL oseltamivir
carboxylate
696285 248693 1936101
0.01 mg/mL oseltamivir
carboxylate
3596256 5836122 4426153
0.032 mg/mL oseltamivir
carboxylate
4656291 4376355 3176164
Synergy volumes represent the sum of the synergy or antagonism across all
concentrations of two drugs for a double combination, or all concentrations of
two drugs at a fixed concentration of the third drug for the TCAD regimen. The
concentrations of each drug used are provided in Table S1. Combinations with
synergy volumes .100 mg/mL
2% for double combinations or .100 mg/mL
3%
for triple combinations are considered to be strongly synergistic (using the
lower 95% confidence interval). Conversely, combinations with synergy
volumes ,2100 mg/mL
2%o rmg/mL
3% are considered to be strongly
antagonistic. Bold numbers denote volumes that are defined as strongly
synergistic or antagonistic. Synergy volumes are presented as the mean
between replicates with 95% confidence intervals. Typically, between 3 and 6
experiments were run for each combination, with each experiment having 3
replicate wells for each condition.
doi:10.1371/journal.pone.0009332.t001
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single agent, indicative that each drug was active at lower
concentrations (greater potency). For example, the EC50 for
amantadine as a single agent was reduced by 3.2-fold in
combination with 1 mg/mL ribavirin and 0.0032 mg/mL oselta-
mivir carboxylate; the EC50 for ribavirin as a single agent was
reduced by 2.7-fold in combination with 0.0032 mg/mL oselta-
mivir carboxylate and 1 mg/mL amantadine; and the EC50 for
oseltamivir carboxylate as a single agent was reduced 16.2-fold in
combination with 1 mg/mL ribavirin and 1 mg/mL amantadine
(Table 2). For all three drugs, the reduction in EC50 values
observed in the triple combination compared to the single agent
was statistically significant (P,0.05), indicative that each drug had
greater antiviral potency and was effective at lower concentrations.
In addition, the EC50 of all three drugs in triple combination were
reduced 1.5- to 6.5-fold compared to the EC50 in double
combinations, indicative of that the antiviral activity of the drugs
in triple combination were enhanced compared to double
combinations.
Importantly, the data presented here do not represent the
maximum reductions in EC50 values for the three drugs. Due to
the dynamic range of the assay, we were only able to obtain
precise dose-response curves for each drug at fixed concentrations
of the second and third drugs which were well below their EC50
values and well below concentrations where maximum synergy
occurred. At higher concentrations, the antiviral activity of the
second and third drug contributed significantly to the inhibition,
which decreased the linear range of the assay and reduced the
accuracy of the curve-fitting (data not shown). A comprehensive
assessment of the interaction of two or three drugs in combination
requires the evaluation of multiple concentrations of each drug in
order to quantify synergy over the entire dosing range, as was done
in the section above.
Synergy of Double Combinations of Neuraminidase
Inhibitors against 2009 H1N1
We also evaluated the interactions of double combinations of
neuraminidase inhibitors (NAIs) against 2009 H1N1. As shown in
Table 1, the synergy volumes for the zanamivir/oseltamivir
carboxylate were 2246116 mg/mL
2%, 2155689 mg/mL
2%,
and 2197698 mg/mL
2% against CA04, CA05, and CA10,
respectively. These values suggest that the zanamivir/oseltamivir
carboxylate combination was additive against these viruses. For
the zanamivir/peramivir combination, synergy volumes were
2356112 mg/mL
2%, 21976108 mg/mL
2% and 2239693 mg/
mL
2% against CA04, CA05, and CA10, respectively, indicative of
additivity to moderate antagonism. Consistent with these values,
the synergy plots for the NAI double combinations against CA05
revealed regions of antagonism (red areas), which occurred at
higher concentrations of zanamivir (0.01–0.1 mg/mL) and at
variable concentrations of the second NAI (oseltamivir or
peramivir, Figure S2). Similar results were found with the other
two 2009 H1N1 strains. Furthermore, evaluation of the EC50 of
each NAI in combination with a fixed concentration of a second
NAI revealed that the antiviral activity of each drug was not
enhanced in combination with a second drug (data not shown).
The observation that double combinations of neuraminidase
inhibitors were not synergistic is consistent with the fact that all
three drugs are known to target the same enzyme, and all bind in
the same substrate binding pocket in a similar manner [19].
Activity of Amantadine in the Context of the TCAD
Regimen against Seasonal and Avian Amantadine-
Resistant Viruses
As an extension of these studies we assessed the contribution
of amantadine to the synergy of the TCAD regimen against
Figure 1. Synergy of double and triple combinations of amantadine, ribavirin, and oseltamivir carboxylate against 2009 H1N1.
Amantadine-resistant 2009 H1N1 viruses were incubated with MDCK cells in the presence of drugs, and CPE was determined by Neutral Red assay.
Synergy volumes are plotted for each double combination, and for the triple combination as a function of increasing concentration of each drug as
the third drug. Gray bars, A/California/04/09 (CA04); black bars, A/California/05/09 (CA05); hatched bars, A/California/10/09 (CA10). (A) Double
combinations of amantadine/oseltamivir carboxylate (AMT/OSC), amantadine/ribavirin (AMT/RBV), and ribavirin/oseltamivir carboxylate (RBV/OSC).
Triple combination of amantadine, ribavirin, and oseltamivir carboxylate as a function of (B) amantadine concentration, (C) ribavirin concentration,
and (D) oseltamivir carboxylate concentration. Data are presented as the mean between 18 replicates from 6 experiments with 95% confidence
intervals. The concentrations of each drug used in double and triple combinations are provided in Table S1. *P,0.05 versus double combination
without drug.
doi:10.1371/journal.pone.0009332.g001
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amantadine-resistant viruses tested included A/New Caledonia/
20/99 (H1N1) bearing the V27A substitution in M2 (NC V27A),
A/Wisconsin/67/05 (H3N2) bearing the S31N substitution in
M2 (WI S31N), and A/Duck/MN/1525/81 (H5N1) bearing the
A30T substitution in M2 (DK A30T). As a single agent,
amantadine had no activity against these viruses at concentra-
tions up to the highest concentration tested (32 mg/mL; data not
shown). As shown in Figure 2, against NC V27A and WI S31N,
amantadine contributed to the synergy of the TCAD regimen in
a concentration-dependent manner. The synergy of the TCAD
regimen in the presence of amantadine was greater than the
synergy of the ribavirin/oseltamivir carboxylate double combi-
nation without amantadine, and the increase in the synergy of
the TCAD regimen was observed at 0.32 mg/mL amantadine
for NC V27A and 1 mg/mL amantadine for WI S31N, when
significance was evaluated at the level of ,0.05. Against DK
A30T, however, amantadine did not make a contribution to the
synergy of the TCAD regimen within the concentration range
tested (0.1–3.2 mg/mL), and the synergy of the TCAD regimen
was not greater than the synergy of the ribavirin/oseltamivir
carboxylate double combination. Whether the lack of contribu-
tion from amantadine against the DK A30T virus was due to the
specific subtype (H5N1), the M2 mutation (A30T), or the
combination of both remain to be determined. However, it
should be noted that while amantadine made no contribution to
the activity of the TCAD regimen against DK A30T, both
ribavirin and oseltamivir remain active and their interactions
were additive, indicative that two out of three drugs contribute
to the activity of the TCAD regimen against this virus (data not
shown).
Activity of Oseltamivir in the Context of the TCAD
Regimen against Oseltamivir-Resistant Viruses
Given that a large percentage of seasonal influenza circulating
viruses are resistant to oseltamivir, we next assessed the activity
and synergy of the TCAD regimen against oseltamivir-resistant
viruses to evaluate the spectrum of activity of the TCAD regimen,
and to determine whether oseltamivir contributed to the activity of
the TCAD regimen against oseltamivir-resistant viruses. Two
H1N1 oseltamivir-resistant viruses were used, both of which bear
the H274Y substitution in NA which has been demonstrated to
confer resistance to oseltamivir [20]: A/Mississippi/3/01 (MS
H274Y) and A/Hawaii/21/07 (HI H274Y). As a single agent,
oseltamivir carboxylate had no antiviral activity against either
virus below 1 mg/mL (data not shown). The synergy volumes of
double and triple combinations of amantadine, ribavirin, and
oseltamivir were determined against both viruses, and the data are
presented in Figure 3. As double combinations, amantadine/
oseltamivir carboxylate, amantadine/ribavirin, and ribavirin/
oseltamivir carboxylate were all additive (Figure 3A). As was seen
with the 2009 H1N1 viruses, the TCAD regimen was synergistic,
and the synergy volume was greater than the synergy volume of
any double combination, with each drug making a contribution to
the synergy of the TCAD regimen against the oseltamivir-resistant
viruses (Figure 3B–D). Importantly, oseltamivir carboxylate
contributed to the synergy of the TCAD regimen starting at
0.1 mg/mL against MS H274Y (P,0.05) and at 0.32 mg/mL
against HI H274Y (P,0.01). At these concentrations, which are
achievable clinically, oseltamivir carboxylate is not active as a
single agent against these resistant strains. Synergy plots for the
TCAD regimen against MS H274Y and HI H274Y are provided
in Figure S3, and reveal increasing synergy with increasing
Table 2. The 50% effective concentration (EC50) of amantadine, ribavirin, and oseltamivir carboxylate as single agents and in
double and triple combinations against 2009 H1N1 A/California/10/09 (CA10) as determined by Neutral Red assay.
Test Article
EC50
(mg/mL)
95%
Confidence
interval
Fold
Reduction
in EC50
Compared
to (A)
Fold
Reduction
in EC50
Compared
to (B)
Fold
Reduction
in EC50
Compared
to (C)
P-values
Compared
to (A)
P-values
Compared
to (B)
P-values
Compared
to (C)
Amantadine
( A ) a l o n e 2 4 2 3 – 2 5 ––––––
(B) with 1 mg/mL ribavirin 13 12–14 1.8 – – ,0.0001 – –
(C) with 0.0032 mg/mL oseltamivir carboxylate 12 11–14 2.0 – – ,0.0001 – –
(D) with 1 mg/mL ribavirin and 0.0032 mg/mL
oseltamivir carboxylate
7.6 6.0–9.6 3.2 1.7 1.6 ,0.0001 ,0.0001 ,0.0001
Ribavirin
(A) alone 6.5 6.2–6.9 – – ––––
(B) with 0.0032 mg/mL oseltamivir carboxylate 3.5 3.2–3.9 1.9 – – ,0.0001 – –
(C) with 1 mg/mL amantadine 5.2 4.6–5.9 1.2 – – 0.007 – –
(D) with 0.0032 mg/mL oseltamivir carboxylate
and 1 mg/mL amantadine
2.4 1.7–3.4 2.7 1.5 2.2 ,0.0001 0.0143 ,0.0001
Oseltamivir carboxylate
(A) alone 0.055 0.037–0.081 – – ––––
(B) with 1 mg/mL ribavirin 0.022 0.015–0.032 2.5 – – 0.0009 – –
(C) with 1 mg/mL amantadine 0.022 0.012–0.037 2.5 – – 0.003 – –
(D) with 1 mg/mL ribavirin and 1 mg/mL
amantadine
0.0034 0.0009–0.012 16.2 6.5 6.5 ,0.0001 0.0437 0.0015
EC50 values are the mean of five experiments (three replicates per experiment).
doi:10.1371/journal.pone.0009332.t002
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tration of oseltamivir carboxylate tested (3.2 mg/mL), synergy
occurred over wide concentrations of ribavirin and amantadine.
At lower concentrations of oseltamivir carboxylate, synergy
occurred at higher concentrations of amantadine (0.1 mg/mL or
higher), and at wide concentrations of ribavirin. No significant
antagonism was detected at any concentrations of the three drugs.
We also determined the EC50 of oseltamivir carboxylate as a
single agent and in double and triple combinations against both
oseltamivir-resistant viruses. As summarized in Table 3, the EC50
of oseltamivir carboxylate as a single agent was 74 mg/mL against
MS H274Y and 15 mg/mL against HI H274Y. These represent
1480- and 300-fold reductions in susceptibility compared to the
published values for a wild-type virus [11]. The EC50 of
oseltamivir carboxylate was not reduced in double combination
with 1mg/mL ribavirin or 0.032 mg/mL amantadine against MS
H274Y, and was reduced by only 1.7- and 1.4-fold, respectively,
against HI H274Y. However, in triple combination with ribavirin
and amantadine at the same concentrations used in double
combination, the EC50 of oseltamivir carboxylate was reduced by
21-fold against MS H274Y and by 5.8-fold against HI H274Y.
Cytotoxicity of Antiviral Drugs as Single Agents and in
Double and Triple Combinations
The TC50 of amantadine as a single agent was 37–40 mg/mL,
whereas the TC50 of ribavirin and oseltamivir carboxylate as single
agents were .100 mg/mL (Table S2). These values are more than
10-fold higher than the highest concentration of each drug used in
the combination experiments (Table S1). Furthermore, synergy
analysis of the double and triple combinations revealed no
synergistic cytotoxicity for any double combination or the TCAD
regimen within the concentration ranges tested (data not shown).
Figure 2. Synergy of the TCAD regimen against seasonal and
avian amantadine-resistant viruses. Amantadine-resistant seasonal
and avian viruses were incubated with MDCK cells in the presence of
drugs, and CPE was determined by Neutral Red assay. Synergy volumes
are plotted as a function of amantadine concentration, with 0 mg/mL
amantadine being the ribavirin/oseltamivir carboxylate double combi-
nation. Gray bars, A/New Caledonia/20/99 (H1N1) V27A (NC V27A);
black bars, A/Wisconsin/67/05 (H3N2) S31N (WI S31N); hatched bars, A/
Duck/MN/1525/81 (H5N1) A30T (DK A30T). Data are presented as the
mean between 10 replicates from 4 experiments with 95% confidence
intervals for NC V27A, 27 replicates from 9 experiments with 95%
confidence intervals for WI S31N, and 12 replicates from 4 experiments
with 95% confidence intervals for DK A30T. The concentrations of each
drug used in double and triple combinations are provided in Table S1.
*P,0.05 versus double combination without amantadine.
doi:10.1371/journal.pone.0009332.g002
Figure 3. Synergy of double and triple combinations of amantadine, ribavirin, and oseltamivir carboxylate against oseltamivir-
resistant H1N1. Oseltamivir-resistant H1N1 viruses were incubated with MDCK cells in the presence of drugs, and CPE was determined by Neutral
Red assay. Synergy volumes are plotted for each double combination, and for the triple combination as a function of increasing concentration of
each drug as the third drug. Black bars, A/Mississippi/3/01 H274Y (MS H274Y); hatched bars, A/Hawaii/21/07 H274Y (HI H274Y). (A) Double
combinations of amantadine/oseltamivir carboxylate (AMT/OSC), amantadine/ribavirin (AMT/RBV), and ribavirin/oseltamivir carboxylate (RBV/OSC).
Triple combination of amantadine, ribavirin, and oseltamivir carboxylate as a function of (B) amantadine concentration, (C) ribavirin concentration,
and (D) oseltamivir carboxylate concentration. Data are presented as the mean between 18 replicates from 6 experiments with 95% confidence
intervals. The concentrations of each drug used in double and triple combinations are provided in Table S1. *P,0.05 versus double combination
without drug.
doi:10.1371/journal.pone.0009332.g003
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concentrations tested for all three drugs used in the combination
experiments (3.2 mg/mL amantadine, 10 mg/mL ribavirin, and
3.2 mg/mL oseltamivir carboxylate) exhibited 97% viability, which
was not statistically different than the cell control (P=0.47 as
determined by Student’s t-test, Figure S4).
Inhibitory Quotients of Antiviral Drugs against
Susceptible and Resistant Viruses
One indicator of the expected clinical antiviral activity is the
inhibitory quotient (IQ), defined herein as the ratio between the
average total plasma concentration (Cave) and the 50% effective
inhibitory concentration (EC50). In order to predict the
effectiveness of the TCAD regimen against the circulating
influenza strains in the clinical setting, we calculated and
compared the IQs for amantadine, ribavirin, and oseltamivir
carboxylate as single agents and the TCAD regimen against
susceptible and resistant influenza viral strains (including 2009
H1N1). To determine the IQ of the TCAD regimen, amanta-
dine, ribavirin, and oseltamivir ca r b o x y l a t ew a st e s t e da saf i x e d
ratio combination, wherein the ratio of the three drugs was kept
constant even as the total concentration of drugs varied. A
dilution curve of the TCAD regimen was created by first
preparing a solution of all three drugs at 100-fold the Cave of each
drug (43 mg/mL amantadine, 130 mg/mL ribavirin, 30 mg/mL
oseltamivir carboxylate), and then serially diluting this solution in
half-log10 increments. In this manner, the EC50 of the TCAD
regimen was determined as a ratio of the Cave a n de x p r e s s e di n
units of fold change from Cave.
As representatives of the current circulating strains, we used A/
New Caledonia/20/99 (H1N1) (NC20) as the susceptible virus
(susceptible to amantadine, ribavirin, and oseltamivir carboxylate),
CA10 as the amantadine-resistant virus, and MS H274Y as the
oseltamivir-resistant virus. Concentration-response curves for
amantadine, ribavirin, oseltamivir carboxylate, and TCAD were
generated against all three viruses, and the EC50s and IQs are
summarized in Table 4. Amantadine was effective at inhibiting
NC20 and MS H274Y in vitro, resulting in IQs of 1.95 and 7.17,
respectively. However, the IQ for amantadine was reduced to 0.02
when tested against CA10, indicative that an in vitro concentra-
tion representing the achievable plasma concentration at the
recommended dose was not adequate to inhibit the amantadine-
resistant virus in vitro. An IQ of 0.02 represents a 100-fold
reduction compared to NC20 and a 350-fold reduction compared
to MS H274Y. Similarly, oseltamivir carboxylate was effective at
inhibiting NC20 and CA10 in vitro resulting in IQs of 1.5 and 5.0,
respectively, but not MS H274Y (IQ=0.004). Similar to
amantadine against the amantadine-resistant virus, the IQ for
oseltamivir was reduced 350- to 2300-fold against the oseltamivir-
resistant virus compared to susceptible viruses. The IQs for
ribavirin were uniformly low and below 1 for all three viruses (0.23
to 0.42). On the other hand, the IQs for the TCAD regimen as a
fixed dose combination were consistently high against all three
viruses (8.33 to 17.24), varying by no more than 2-fold between
susceptible and resistant viruses. These data suggest that the
TCAD regimen may have broad utility against all circulating
influenza strains, including strains that are resistant to either
amantadine or oseltamivir.
Discussion
Given that virtually all seasonal H3N2 and 2009 H1N1 strains
are resistant to amantadine, and virtually all currently circulating
seasonal H1N1 strains are resistant to oseltamivir, the pharmaco-
logic rationale for the development of a triple combination
antiviral drug (TCAD) composed of amantadine, ribavirin,
oseltamivir is that at least two, and possibly three drugs, in the
TCAD regimen will be active against all of these viruses. A
number of studies have evaluated double combinations of
antivirals [21–27] against influenza A infection in vitro, and
Hayden et al. have tested a triple combination of two antivirals
with human interferon a [28]. However, there have been few
reports on the effects of drug combinations on resistant influenza
viruses [26,27,29]. Recently, Smee et al. evaluated the effects of
double combinations of amantadine, ribavirin, and oseltamivir
against the same amantadine-resistant H5N1 virus used in this
Table 3. The 50% effective concentration (EC50) of oseltamivir carboxylate as single agents and in double and triple combinations
against seasonal oseltamivir-resistant viruses as determined by Neutral Red assay.
Regimen
EC50
(mg/mL)
95%
Confidence
interval
Fold
Reduction
in EC50
Compared
to (A)
Fold
Reduction
in EC50
Compared
to (B)
Fold
Reduction
in EC50
Compared
to (C)
P-values
Compared
to (A)
P-values
Compared
to (B)
P-values
Compared
to (C)
Against A/Mississippi/3/01 (H1N1) H274Y
(A) oseltamivir carboxylate alone 73 46–114 – – ––––
(B) with 1.0 mg/mL ribavirin .1 0 0 ––––0 . 1 1 2 7 ––
(C) with 0.032 mg/mL amantadine .1 0 0 ––––0 . 0 9 2 0 ––
(D) with 1 mg/mL ribavirin and 0.032 mg/mL
amantadine
3.4 1.2–9.6 21 .29 .29 ,0.001 ,0.0001 ,0.0001
Against A/Hawaii/21/07 (H1N1) H274Y
(A) oseltamivir carboxylate alone 15 9–23 – – ––––
(B) with 1 mg/mL ribavirin 8.7 5–14 1.7 – – 0.1383 – –
(C) with 0.032 mg/mL amantadine 11 5–25 1.4 – – 0.5379 – –
(D) with 1 mg/mL ribavirin and 0.032 mg/mL
amantadine
2.6 1.1–6.3 5.8 3.3 4.2 0.0010 0.0189 0.0218
EC50 values are the mean of five experiments (three replicates per experiment).
doi:10.1371/journal.pone.0009332.t003
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presence of amantadine in double combinations did not provide
added benefit over the second drug alone, either in cell culture or
in mouse models.
In the present study, we examined the efficacy and synergy of
the TCAD regimen against viruses which were resistant to
oseltamivir or amantadine, including 2009 H1N1. Consistent with
the previous findings [9], we found that the 2009 H1N1 strains
were susceptible to NAIs (oseltamivir carboxylate, zanamivir, and
peramivir) and ribavirin, but were resistant to adamantanes
(amantadine and rimantadine). Surprisingly, we found that
amantadine as a single agent retained partial activity against
these viruses (Table S2), albeit the activity was reduced by 100-fold
compared to a susceptible virus, whereas rimantadine had no
activity below the 50% cytotoxic concentration. This observation
suggests that phenotypic testing, in addition to determination of
the genotype, may be necessary in order to fully understand the
susceptibility profile of a novel virus and may have important
implications in guiding the choice of antivirals for use in
combinations.
Against the 2009 H1N1 strains, the interactions of oseltamivir
carboxylate, peramivir, and zanamivir in double combinations
ranged from additive to moderately antagonistic, indicative that
the activity of these drugs was not enhanced in combination
compared to their activity as single agents. These results suggest
that double combinations of NAIs may not provide any added
benefit over the drugs as single agents. Given that all NAIs bind in
the same substrate binding pocket in NA, the use of these drugs in
combination in the absence of enhanced activity raises the risk of
selecting for a single mutation that could confer resistance to both
neuraminidase inhibitors simultaneously. Indeed, cross-resistance
to oseltamivir and zanamivir resulting from a single amino acid
change has been documented for seasonal influenza A and B
viruses [30]. If this were to occur in the 2009 H1N1 background,
the resulting virus would be resistant to all approved anti-influenza
drugs.
In total, we tested the activity and synergy of the TCAD
regimen against six amantadine-resistant viruses, including three
strains of 2009 H1N1, and two oseltamivir-resistant viruses. The
viruses tested in this study come from the three subtypes that cause
significant morbidity and mortality in humans (H1N1, H3N2, and
H5N1), and include seasonal, avian, and pandemic strains. The
double combinations of amantadine/oseltamivir carboxylate,
amantadine/ribavirin, and ribavirin/oseltamivir carboxylate were
additive against 2009 H1N1, and ranged from additive to
moderately synergistic against the other viruses (data not shown).
In contrast, with the exception of the duck H5N1 virus, we found
that the TCAD regimen was synergistic at clinically achievable
concentrations of all three drugs, and that the synergy of the
TCAD regimen was greater than that of any double antiviral drug
combination. These data suggest that the TCAD regimen may
have broad-spectrum antiviral activity against circulating influenza
A viruses, including strains that are resistant to either classes of
antivirals. To date, most influenza A strains in circulation (,99%)
are resistant to either the adamantanes or oseltamivir, and not to
both [31], and thus are expected to be susceptible to the TCAD
regimen. Currently, rapid diagnostic tests are not available to
determine the susceptibility profile of influenza viruses in real time,
and thus clinicians do not often have the necessary information
with which to guide appropriate antiviral use. The availability of a
broad-spectrum antiviral therapy that would be effective against
the majority of circulating strains regardless of the susceptibility
would be of high clinical utility.
Importantly, we found that amantadine and oseltamivir
contributed to the synergy of the TCAD regimen against
amantadine-resistant and oseltamivir-resistant viruses. The con-
tributions from both drugs to the synergy of the TCAD regimen
were significant at clinically achievable concentrations where they
Table 4. The 50% effective concentrations (EC50) and inhibitory quotients (IQ) for amantadine, ribavirin, oseltamivir carboxylate,
and TCAD
a against representative susceptible and resistant viruses.
Strain Regimen
EC50
(mg/mL)
95% Confidence
Interval
EC50
(fold Cave)
b
95% Confidence
Interval IQ (Cave/EC50)
A/New Caledonia/20/99 (H1N1)
susceptible
Amantadine 0.22 0.13–0.39 – – 1.95
Ribavirin 3.1 2.1–4.5 – – 0.42
Oseltamivir carboxylate 0.20 0.14–0.28 – – 1.50
TCAD – – 0.058 0.045–0.074 17.24
A/California/10/09 (H1N1) S31N
amantadine-resistant
Amantadine 20 16–24 – – 0.02
Ribavirin 3.2 01.6–4.8 – – 0.41
Oseltamivir carboxylate 0.032 0.30–0.34 – – 9.38
TCAD – – 0.065 0.044–0.095 15.38
A/Mississippi/3/01 (H1N1) H274Y
oseltamivir-resistant
Amantadine 0.060 0.047–0.073 – – 7.17
Ribavirin 3.6 2.8–4.6 – – 0.36
Oseltamivir carboxylate 73 46–114 – – 0.004
TCAD – – 0.12 0.085–0.17 8.33
EC50 values are the mean of three to five experiments (three replicates per experiment).
aTCAD, triple combination antiviral drug (amantadine, ribavirin, and oseltamivir carboxylate) as a fixed-ratio combination.
bTCAD was formulated as a fixed-ratio combination based on the Cave of each drug, wherein at 1-fold Cave each drug was present at the following concentration:
0.43mg/mL amantadine, 0.3 mg/mL oseltamivir carboxylate, and 1.3 mg/mL ribavirin. TCAD was then titrated keeping the ratio of the drugs constant. The EC50 of TCAD
is expressed as a ratio to the Cave.
doi:10.1371/journal.pone.0009332.t004
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comparison of the synergy volume of the TCAD regimen at
0.32 mg/mL amantadine to the synergy volume of the ribavirin/
oseltamivir carboxylate double combination (no amantadine)
revealed that amantadine contributed 39%, 24%, and 44% to
the total synergy of the TCAD regimen against CA04, CA05, and
CA10, respectively. Similarly, against the oseltamivir-resistant
viruses, oseltamivir carboxylate at 0.32 mg/mL contributed 76%
and 83% to the total synergy of the TCAD regimen against MS
H274Y and HI H274Y, respectively. Thus, all three drugs
contributed to the synergy and activity of the TCAD regimen
against amantadine- and oseltamivir-resistant viruses, and the
activities of amantadine and oseltamivir were restored in the
context of the TCAD regimen against influenza strains that were
resistant to these drugs, thereby maximizing the clinical utility of
these drugs.
The mechanism(s) by which amantadine and oseltamivir
carboxylate contribute to the synergy of the TCAD regimen
against resistant strains is unclear. The interactions between M2,
HA, and NA on the surface of the influenza particle are complex
and not well understood, and a number of studies have
demonstrated that HA-M2 and HA-NA interactions can affect
the susceptibility to amantadine and oseltamivir, respectively
[32,33]. Furthermore, amantadine has been demonstrated to exert
antiviral activity via interactions with HA at higher concentrations
[34,35]. It is conceivable that, as the result of protein-protein
interactions between M2, HA, and NA, the binding of a drug at
one site may affect the conformation and therefore affinity for
another drug at another site. The mechanism by which ribavirin
contributes to the synergy of the TCAD regimen is also unclear.
Ribavirin has been documented to act through multiple
mechanisms affecting both virus replication and host immune
response [36–38], and it remains to be elucidated which of these
mechanisms are responsible for the synergy with amantadine and
oseltamivir.
Finally, we evaluated the activity and inhibitory quotient (IQ) of
TCAD against susceptible and resistant viruses representing the
currently circulating strains. While the correlation between IQ and
clinical efficacy has not been demonstrated for influenza, it is
valuable to construct a relative ranking of the IQ of different
antiviral regimens against susceptible and resistant viruses in order
to assess the spectrum of their activity. When tested against a
seasonal susceptible H1N1 virus, an amantadine-resistant 2009
H1N1, and a seasonal oseltamivir-resistant H1N1 virus, TCAD
was uniformly active against all three viruses with significantly
high IQs (8.33 to 17.24; Table 4). This suggests that TCAD may
have broad antiviral activity against all currently circulating
influenza strains and may have good efficacy in the clinical setting
against these strains.
Our data suggests that a triple combination antiviral drug
(TCAD) composed of amantadine, ribavirin, and oseltamivir may
be an effective and viable therapeutic option for the treatment of
pandemic and seasonal influenza infection. The body of data
presented in this report validates the TCAD hypothesis, which
states that for any given susceptible or resistant circulating
influenza virus, at least two, and in some cases all three, drugs
in TCAD will be active. Furthermore, the TCAD regimen appears
to overcome baseline drug resistance and thus may represent a
highly active antiviral therapy for seasonal and pandemic
influenza. The safety, pharmacokinetics, distribution, and metab-
olism of amantadine, ribavirin, and oseltamivir as single agents are
well understood, and it is not expected that co-administration of
the three drugs will result in substantially increased risk to patients
compared to the administration of the individual drugs. In
addition, all three double combinations have been tested in
humans without adverse effects, including amantadine plus
oseltamivir [39], amantadine plus ribavirin [40], and ribavirin
plus oseltamivir [41]. Clinical trials to assess the efficacy and safety
of TCAD for the treatment of influenza have been initiated, and
will provide important data on the use of TCAD against both
pandemic and seasonal influenza.
Supporting Information
Table S1 Concentration ranges (mg/mL) of each drug tested in
double and triple combinations against different influenza A
viruses. Drugs were titrated at half log10 increments. NT, not
tested. CA04, A/California/04/09 (H1N1); CA05, A/California/
05/09 (H1N1); CA10, A/California/10/09 (H1N1); NC V27A,
A/New Caledonia/20/99 (H1N1); WI S31N, A/Wisconsin/67/
05 (H3N2); DK A30T, A/Duck/MN/1525/81 (H5N1); MS
H274Y, A/Mississippi/3/01 (H1N1); HI H274Y, A/Hawaii/21/
07 (H1N1).
Found at: doi:10.1371/journal.pone.0009332.s001 (0.05 MB
DOC)
Table S2 The 50% effective concentrations (EC50) with 95%
confidence intervals (95% CI), and 50% cytotoxic concentrations
(TC50) of different antiviral agents against 2009 H1N1 viruses.
EC50 and TC50 values are the mean of at least 5 experiments
(three replicates per experiment) as determined by Neutral Red
assay. CA04, A/California/04/09; CA05, A/California/05/09;
CA10, A/California/10/09.
aRimantadine was not active up to
the 50% cytotoxic concentration.
Found at: doi:10.1371/journal.pone.0009332.s002 (0.06 MB
DOC)
Figure S1 Synergy plot of double and triple combinations of
amantadine, ribavirin, and oseltamivir carboxylate against 2009
H1N1 A/California/05/09 (CA05) replication as determined by
Neutral Red assay in MDCK cells. Calculated additive interac-
tions were subtracted from the experimentally determined
inhibition to reveal regions of synergy (inhibition above expected)
or antagonism (inhibition below expected). Values were derived
from mean triplicate data and presented at 95% confidence. This
experiment was repeated a total of six times with similar results.
Blue areas indicate concentrations of each drug that are
synergistic, gray areas indicate concentrations that are additive,
and red areas indicate concentrations that are antagonistic. The
intensity of the color (blue or red) corresponds to percent
inhibition above or below expected. (A) Double combinations of
amantadine/oseltamivir carboxylate (top); amantadine/ribavirin
(middle); and ribavirin/oseltamivir carboxylate (bottom). Concen-
trations of each drug are indicated on the axes. (B) Triple
combinations of amantadine, ribavirin, and oseltamivir carboxyl-
ate. Concentrations of each drug are indicated on the axes, with
each plane representing a different concentration of amantadine.
Found at: doi:10.1371/journal.pone.0009332.s003 (5.74 MB TIF)
Figure S2 Synergy plot of double combinations of zanamivir,
oseltamivir carboxylate, and peramivir against 2009 H1N1 A/
California/05/09 (CA05) replication as determined by Neutral
Red assay in MDCK cells. Values were derived from mean
triplicate data and presented at 95% confidence. This experiment
was repeated a total of three times for the zanamivir/oseltamivir
carboxylate combination and four times for the zanamivir/
peramivir combination with similar results. Blue areas indicate
concentrations of each drug that are synergistic, gray areas
indicate concentrations that are additive, and red areas indicate
concentrations that are antagonistic. Double combination of (A)
Combination Drug for Influenza
PLoS ONE | www.plosone.org 10 February 2010 | Volume 5 | Issue 2 | e9332zanamivir and oseltamivir carboxylate; and (B) zanamivir and
peramivir. Concentrations of each drug are indicated on the axes.
Found at: doi:10.1371/journal.pone.0009332.s004 (2.20 MB TIF)
Figure S3 Synergy of triple combinations of amantadine,
ribavirin, and oseltamivir carboxylate against A/Mississippi/3/
01(H1N1) H274Y (MS H274Y) and A/Hawaii/21/07 (H1N1)
H274Y (HI H274Y) replication as determined by Neutral Red
assay in MDCK cells. Values were derived from mean triplicate
data and presented at 95% confidence. This experiment was
repeated a total of six times with similar results. Blue areas indicate
concentrations of each drug that are synergistic, gray areas
indicate concentrations that are additive, and red areas indicate
concentrations that are antagonistic. (A) MS H274Y; (B) HI
H274Y. Concentrations of each drug are indicated on the axes,
with each plane representing a different concentration of
oseltamivir carboxylate.
Found at: doi:10.1371/journal.pone.0009332.s005 (4.13 MB TIF)
Figure S4 Viability of MDCK cells treated with the TCAD
regimen. MDCK cells were incubated with the TCAD regimen at
the highest concentrations of all three drugs used in the synergy
experiments (3.2 mg/mL amantadine, 10 mg/mL ribavirin, and
3.2 mg/mL oseltamivir carboxylate), and cell viability was
determined by Neutral Red assay after 72 hours. Values are the
mean of nine replicates from three experiments, with standard
deviations. The difference in viability between the TCAD treated
cells and the cell controls was not statistically significant (P=0.47,
Student’s t-test).
Found at: doi:10.1371/journal.pone.0009332.s006 (1.00 MB TIF)
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